News on immunoassay systems and applications.
Oxford Immunotec said that it expects the report to further the trend toward interferon-gamma release assay adoption for healthcare personnel screening.
A Roche executive said he expects essentially all the firm's US troponin customers will convert to the high-sensitivity assay over the next two to three years.
The firm is working with a new center in Dakar, Senegal, that will deploy new tests based on the platform to support early detection of tropical diseases.
Revenues for the quarter were driven by a 27 percent rise in sales volume for the company's OVA1 test.
GenMark Diagnostics received clearance for a third BCID panel that the firm said paves the way for a customizable approach to sepsis MDx.
